Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 67046-721 by Contract Pharmacy Services-pa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

tam0.4.721

tam0.4.721

This is a label of a medicine bottle containing 30 capsules of Tamsulosin, each with a dosage of 0.4 mg. The GTIN code is 00367046721307, and the lot number is TMSA18257-A. The pill identifier is D53. The medicine is manufactured by CitronRising and contains Tamsulosin Hydrochloride USP. It is a controlled substance and should be stored in a room temperature of 20-25°C. The NDC number is 67046-721-30.*

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

The text is a figure caption depicting a graph of mean plasma concentrations of Tamsulosin Hydrochloride Capsules 0.4 mg under fasted and fed conditions over time. Therefore, it doesn't provide any useful description of the data presented in the graph.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2A	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

The text is a description of a figure depicting the mean change from baseline in Total AUA Symptom Score (ranging from 0 to 35) in Study 1. The figure shows the treatment (0.08mg A, 0.4mg A, and placebo), mean change, and the duration of treatment weeks (ranging from 0 to 13). Raw scan data is present in the figure.*

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

The figure shows the mean increase in peak urine flow rate (in L/Sec) in Study 1. The treatment groups were 0.08 mg and 0.4 mg, and the placebo group. The mean change in mL/sec is depicted, and the duration of treatment was in weeks. There were different numbers of participants in each group for the duration of treatment.*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

This appears to be a graph with the title "Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2". There are two axes with values, the X-axis representing "Duration of Treatment (weeks)" and the Y-axis representing "Mean Increase in Peak Urine Flow Rate (mL/Sec)". There are also bars indicating data points for different treatments, but without further context it is difficult to determine the specifics.*

Chemical Structure - tamsulosin str

Chemical Structure - tamsulosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.